Demographics and baseline characteristics of patients originally randomised to secukinumab who entered the extension phase
| Characteristic* | Secukinumab 10 mg/kg IV→150 mg SC(N=161) | Secukinumab 10 mg/kg IV→75 mg SC(N=147) |
| Age (years) | 49.5±11.7 | 48.9±11.8 |
| Female, n (%) | 83 (51.6) | 81 (55.1) |
| Weight (kg) | 83.34±19.43 | 83.43±19.50 |
| Time (years) since first diagnosis of PsA | 8.19±8.33 | 7.66±8.31 |
| Disease history and baseline characteristics | ||
| Anti-TNF-naïve, n (%) | 120 (74.5) | 110 (74.8) |
| Methotrexate use, n (%) | 98 (60.9) | 91 (61.9) |
| Systemic glucocorticoid use, n (%) | 28 (17.4) | 22 (15.0) |
| TJC (78 joints) | 24.1±16.95 | 21.6±15.63 |
| SJC (76 joints) | 12.7±9.81 | 11.8±9.91 |
| Psoriasis (≥3% body surface area), n (%) | 89 (55.3) | 82 (55.8) |
| Presence of dactylitis, n (%) | 83 (51.6) | 77 (52.4) |
| Presence of enthesitis, n (%) | 99 (61.5) | 91 (61.9) |
*Results are mean±SD unless otherwise stated.
IV, intravenous; N, number of randomised patients; n, number of patients; PsA, psoriatic arthritis; SC, subcutaneous; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor.